Australia · Delayed Price · Currency is AUD Cyclopharm Statistics
Total Valuation
Cyclopharm has a market cap or net worth of AUD 64.12 million. The enterprise value is 59.68 million.
| Market Cap | 64.12M |
| Enterprise Value | 59.68M |
Important Dates
The next confirmed earnings date is Wednesday, September 2, 2026.
| Earnings Date | Sep 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cyclopharm has 125.73 million shares outstanding. The number of shares has increased by 4.29% in one year.
| Current Share Class | 125.73M |
| Shares Outstanding | 125.73M |
| Shares Change (YoY) | +4.29% |
| Shares Change (QoQ) | +9.16% |
| Owned by Insiders (%) | 10.18% |
| Owned by Institutions (%) | 25.76% |
| Float | 64.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.86 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.37, with a Debt / Equity ratio of 0.24.
| Current Ratio | 3.37 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.41 |
| Interest Coverage | -32.13 |
Financial Efficiency
Return on equity (ROE) is -53.92% and return on invested capital (ROIC) is -62.55%.
| Return on Equity (ROE) | -53.92% |
| Return on Assets (ROA) | -20.30% |
| Return on Invested Capital (ROIC) | -62.55% |
| Return on Capital Employed (ROCE) | -43.30% |
| Weighted Average Cost of Capital (WACC) | 7.28% |
| Revenue Per Employee | 330,989 |
| Profits Per Employee | -176,181 |
| Employee Count | 109 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.14 |
Taxes
| Income Tax | -366,298 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.22% in the last 52 weeks. The beta is 0.59, so Cyclopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -48.22% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.74 |
| Relative Strength Index (RSI) | 46.71 |
| Average Volume (20 Days) | 55,577 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cyclopharm had revenue of AUD 34.42 million and -18.32 million in losses. Loss per share was -0.16.
| Revenue | 34.42M |
| Gross Profit | 19.46M |
| Operating Income | -17.15M |
| Pretax Income | -18.69M |
| Net Income | -18.32M |
| EBITDA | -16.34M |
| EBIT | -17.15M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 12.25 million in cash and 7.80 million in debt, with a net cash position of 4.44 million or 0.04 per share.
| Cash & Cash Equivalents | 12.25M |
| Total Debt | 7.80M |
| Net Cash | 4.44M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 31.86M |
| Book Value Per Share | 0.25 |
| Working Capital | 23.86M |
Cash Flow
In the last 12 months, operating cash flow was -17.75 million and capital expenditures -1.43 million, giving a free cash flow of -19.18 million.
| Operating Cash Flow | -17.75M |
| Capital Expenditures | -1.43M |
| Depreciation & Amortization | 814,479 |
| Net Borrowing | -1.18M |
| Free Cash Flow | -19.18M |
| FCF Per Share | -0.15 |
Margins
Gross margin is 56.52%, with operating and profit margins of -49.82% and -53.23%.
| Gross Margin | 56.52% |
| Operating Margin | -49.82% |
| Pretax Margin | -54.29% |
| Profit Margin | -53.23% |
| EBITDA Margin | -47.46% |
| EBIT Margin | -49.82% |
| FCF Margin | n/a |
Dividends & Yields
Cyclopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.29% |
| Shareholder Yield | -4.29% |
| Earnings Yield | -28.57% |
| FCF Yield | -29.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 28, 2012. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 28, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Cyclopharm has an Altman Z-Score of 1.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.27 |
| Piotroski F-Score | 3 |